Apoptosis

Apoptosis is an autonomous, genetically controlled, orderly death of cells to maintain the stability of the internal environment. Unlike necrosis, apoptosis is not a passive process, but an active one, involving the activation, expression and regulation of a series of genes, and it is not a phenomenon of autologous damage under pathological conditions, but an active death process for better adaptation to the survival environment. Apoptosis is a fundamental biological phenomenon of cells and plays a necessary role in the removal of unwanted or abnormal cells in multicellular organisms. It plays an important role in the evolution of organisms, the stability of the internal environment, and the development of several systems. Apoptosis is not only a specific type of cell death, but also has important biological significance and complex molecular biological mechanisms.

Cat. No.	Product name
BP10826	Erlotinib hydrochloride
BP10826	Erlotinib is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.
BP10071	Esculentic acid
BP10071	Esculentic acid has anti-inflammatory effect, it has protective effects against LPS-induced endotoxic shock may be mediated, at least in part, by regulation the release of inflammatory cytokines and mediators, and protein expression of COX-2 in mice.
BP10672	Etalocib
BP10672	Etalocib is a novel diaryl ether carboxylic acid derivative, is a selective and potent inhibitor of the lipoxygenase pathway either via antagonism of the leukotriene B4 (LTB4) receptor or directly through 5'-lipoxygenase. It has antineoplastic activities.
BP10597	Ethylenediaminetetraacetic acid trisodium salt
BP10597	Edetate Trisodiumis used to bind metal ions in the chelation therapy.
BP10661	Everolimus
BP10661	Everolimus is a potent mTOR inhibitor that binds to FKBP-12. It is used alone or in combination with calcineurin inhibitors.
BP10617	Evocarpine
BP10617	Evocarpine shows antimycobacterial, and vasorelaxant effects, it can inhibit Ca2+ influx through voltage-dependent calcium channels.
BP10735	Ezatiostat
BP10735	Ezatiostat is a tripeptide analog of glutathione that can selectively inhibit GSTP1-1 catalytic activity.
BP10910	Falnidamol
BP10910	Falnidamol (BIBX 1382) is a selective and orally active inhibitor of EGFR tyrosine kinase (IC50: 3 nM).
BP10061	Farudodstat
BP10061	ASLAN003 is an orally active and potent inhibitor of DHODH (Human Dihydroorotate Dehydrogenase) with antitumor activity. It has the potential to be a first-in-class candidate in AML.
BP10440	Fedratinib hydrochloride hydrate
BP10440	Fedratinib hydrochloride hydrate is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.
BP10534	Fenebrutinib
BP10534	Fenebrutinib is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM).
BP10160	Ferulic Acid
BP10160	Ferulic Acid is a highly abundant phenolic phytochemical and a type of organic compound found in the Ferula assafoetida L. or Ligusticum chuanxiong.It can be absorbed by the small intestine and excreted through the urine.
BP10705	FIIN-3
BP10705	FIIN-3 is an irreversible inhibitor of FGFR.
BP10393	Fimepinostat
BP10393	CUDC-907 is an orally bioavailable inhibitor of both phosphoinositide 3-kinase (PI3K) class I and pan-histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon oral administration, CUDC-907 inhibits the activity of both PI3K class I isoforms and HDAC, thereby preventing the activation of the PI3K-AKT-mTOR signal transduction pathway that is often overactivated in many cancer cell types.
BP10111	FIN56
BP10111	FIN56 is a specific inducer of ferroptosis.
BP10570	Flavopiridol
BP10570	Flavopiridol (Alvocidib) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1, 2, 4, 6 versus CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.
BP10259	FLLL32
BP10259	FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).
BP10970	FLT3-IN-10
BP10970	FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). FLT3-IN-10 shows the potential for the treatment of FLT3-mutated acute myeloid leukemia (AML).
BP10521	FN-1501
BP10521	FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively). FN-1501 also has anticancer activity.
BP10733	Fosbretabulin Disodium
BP10733	Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium, a water-soluble prodrug of Combretastatin A4 (CA4), is a microtubule-targeting agent that binds β-tubulin (Kd: 0.4 μM). Fosbretabulin Disodium inhibits the polymerization of tubulin (IC50: 2.4 μM), and also disrupts tumor vasculature.